Research advances in pharmacotherapy for autoimmune hepatitis
10.3969/j.issn.1001-5256.2023.04.026
- VernacularTitle:自身免疫性肝炎的药物治疗进展
- Author:
Xiuying YANG
1
;
Xiaohong DANG
2
;
Yang JIANG
1
Author Information
1. The First Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China
2. Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030000, China
- Publication Type:Review
- Keywords:
Hepatitis, Autoimmune;
Drug Therapy;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(4):915-921
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune hepatitis (AIH) is an immune-mediated chronic inflammatory liver disease. At present, standard treatment is effective in most AIH patients, and second- or third-line pharmacotherapy can be selected for patients who have suboptimal response to standard treatment or cannot tolerate the side-effects of the drugs. Novel therapies are undergoing clinical trials with the further exploration of the pathogenesis of AIH. This article reviews the current research advances in pharmacotherapy for AIH.
